Nivolumab — Dosing in CKD & Dialysis

Nivolumab (Immunotherapy): renal dosing adjustments, dialyzability (Negligible (serum concentrations immediately before and after an intermittent hemodialysis session were in the range seen without renal insufficiency; the authors conclude IHD does not influence nivolumab exposure; Gulikers 2021, PM

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.